Haleon plc (NYSE:HLN) Increases Dividend to $0.12 Per Share

Haleon plc (NYSE:HLN) declared a — dividend on Monday, March 3rd, Wall Street Journal reports. Stockholders of record on Friday, April 25th will be paid a dividend of 0.1166 per share on Thursday, June 5th. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05.

Haleon has a dividend payout ratio of 43.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Haleon to earn $0.49 per share next year, which means the company should continue to be able to cover its $0.23 annual dividend with an expected future payout ratio of 46.9%.

Haleon Stock Up 0.9 %

Shares of NYSE:HLN opened at $10.68 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market capitalization of $48.33 billion, a P/E ratio of 31.40, a P/E/G ratio of 2.82 and a beta of 0.28. The stock has a 50 day moving average price of $9.61 and a 200-day moving average price of $9.84. Haleon has a 52-week low of $7.89 and a 52-week high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, equities research analysts anticipate that Haleon will post 0.43 EPS for the current fiscal year.

Institutional Trading of Haleon

An institutional investor recently bought a new position in Haleon stock. Brighton Jones LLC purchased a new stake in shares of Haleon plc (NYSE:HLN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 19,579 shares of the company’s stock, valued at approximately $187,000. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.